Imaging Features for the Risks for Recurrence After Stereotactic Radiosurgery in Brain Metastasis
- Conditions
- Brain MetastasesRadiosurgery
- Interventions
- Diagnostic Test: Magnetic resonance imaging (MRI)Diagnostic Test: Diffusion-weighted MRIDiagnostic Test: Arterial spin labeling (ASL)Diagnostic Test: Dynamic susceptibility contrast-MRI (DSC-MRI)
- Registration Number
- NCT05868928
- Lead Sponsor
- Asan Medical Center
- Brief Summary
This trial uses multi-parametric magnetic resonance imaging (MRI) to develop and validate imaging risk score to predict radiation necrosis in participants with brain metastasis treated with radiation therapy. Diagnostic procedures, such as multi-parametric magnetic resonance imaging (MRI), may improve the ability to diagnose radiation necrosis early and help establish treatment strategies.
- Detailed Description
PRIMARY OBJECTIVE:
I. To develop an imaging risk score for recurrence after stereotactic radiosurgery (SRS) in brain metastasis using multiparametric MRI.
II. To validate the imaging risk score in retrospective external validation and prospective internal validation test set.
SECONDARY OBJECTIVE:
I. To predict radiation necrosis using imaging risk score.
OUTLINE:
Participants undergo multi-parametric MRI including 3D pre- and contrast-enhanced T1 weighted image, T2 weighted image, diffusion-weighted image, dynamic susceptibility contrast MRI, and arterial spin labeling image before receiving SRS, and every 3 months after SRS.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 132
-
Patients who underwent stereotactic radiosurgery (SRS, gamma-knife radiosurgery or cyberknife radiosurgery) for brain metastases
-
Patients with lesions eligible for SRS :
- One to ten newly diagnosed brain metastases
- Patients without acute neurological symptom
-
Patients with a Karnofsky performance status score of 70 or higher
-
Patients who underwent brain MRI within 1 month of enrollment
-
Patients with measurable enhancing lesions on MRI.
-
Patients who have available reference standard (second-look surgery for recurrence) or available follow up imaging for clinic-radiologic reference standard.
-
A longest diameter > 1.5 cm for tumor habitat analysis.
Exclusion criteria:
- Patients who have undergone prior brain surgery, SRS, or whole-brain radiation therapy.
- Patients who are diagnosed with leukemia, lymphoma, germ-cell tumor, small-cell lung cancer, leptomeningeal disease, or unknown primary tumor.
- Patients with age < 18 years.
- Patients without baseline MRI.
- Patients with nonmeasurable enhancing lesions on MRI : all other lesions, including lesions with longest dimension < 10 mm, lesions with borders that cannot be reproducibly measured, dural metastases, bony skull metastases, and leptomeningeal disease.
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Brain metastases patients who received stereotactic radiosurgery Diffusion-weighted MRI Patients with brain metastases who received stereotactic radiosurgery Brain metastases patients who received stereotactic radiosurgery Arterial spin labeling (ASL) Patients with brain metastases who received stereotactic radiosurgery Brain metastases patients who received stereotactic radiosurgery Magnetic resonance imaging (MRI) Patients with brain metastases who received stereotactic radiosurgery Brain metastases patients who received stereotactic radiosurgery Dynamic susceptibility contrast-MRI (DSC-MRI) Patients with brain metastases who received stereotactic radiosurgery
- Primary Outcome Measures
Name Time Method Time to progression up to 24 months The time from the date of SRS for brain metastasis until the date of progression.
- Secondary Outcome Measures
Name Time Method Response rate up to 24 months The response is determined by response assessment in neuro-oncology brain metastases (RANO-BM) criteria. Clinical and radiologic assessments per lesion and person are carried out at every MRI follow-up using the MRI before SRS as the baseline.
Occurence rate of radiation necrosis 12 months The rate of occurrence of radiation necrosis per lesion is determined through a combination of imaging findings and clinical evaluation by a multidisciplinary team.
Tumor habitat analysis Baseline imaging before SRS, and follow up imaging every 3 months after SRS, up to 24 months Automated process of tumor habitat analysis will include followings.
A. Methods: preprocessing includes registration, deep learning segmentation, and normalization of contrast-enhanced T1-weighted (CE-T1) and T2-weighted images. K-means clustering is applied to CE-T1-weighted and T2-weighted images to construct structural MRI habitats and to apparent diffusion coefficient (ADC) and cerebral blood volume (CBV) images to construct physiologic habitats.
B. Structural MRI habitats: enhancing tissue habitat, solid low-enhancing habitat, and nonviable tissue habitat
C. Physiologic MRI habitats: hypervascular cellular habitat, hypovascular cellular habitat, and nonviable tissue habitat..
D. Quantitative measurement of each habitat will be performed.Imaging risk score for recurrence Baseline imaging before SRS, and follow up imaging every 3 months after SRS, up to 24 months To calculate the imaging risk score, three parameters are added together, namely the "solid component score," the "less enhancing component score," and the "blood flow score," using contrast-enhanced T1-weighted image(T1WI), T2-weighted image (T2WI), diffusion-weighted imaging (DWI), and ASL.
The solid component risk score is assigned 0, 1, or 2 points, depending on whether the hypointense lesion on T2WI matches the enhancement in CE-T1WI.
The less-enhancing component risk score evaluates the degree of enhancement of the lesion to the dura. It assigns 0, 1, or 2 points depending on whether it is brighter, similar, or less enhanced.
The blood flow risk score assigns 0, 1, or 2 points based on the degree of blood flow of the lesion in ASL.
Trial Locations
- Locations (1)
Asan Medical Center
🇰🇷Seoul, Korea, Republic of